Drug Profile
Research programme: biosimilars - Biocon/Sandoz
Alternative Names: Immunology biologics - Biocon/Sandoz; Next-generation biosimilars - Biocon/Sandoz; Oncology biologics - Biocon/SandozLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Biocon; Sandoz
- Class Antineoplastics; Biological factors; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in India (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Immunological-disorders in Germany (Parenteral)